Update of the evidence based, interdisciplinary guideline for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis.

Heiligenhaus, A; Minden, K; Tappeiner, Christoph; Baus, H; Bertram, B; Deuter, C; Foeldvari, I; Föll, D; Frosch, M; Ganser, G; Gaubitz, M; Günther, A; Heinz, C; Horneff, G; Huemer, C; Kopp, I; Lommatzsch, C; Lutz, T; Michels, H; Neß, T; ... (2019). Update of the evidence based, interdisciplinary guideline for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis. Seminars in arthritis and rheumatism, 49(1), pp. 43-55. Elsevier 10.1016/j.semarthrit.2018.11.004

[img]
Preview
Text
1-s2.0-S0049017218304621-main.pdf - Published Version
Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND).

Download (632kB) | Preview

BACKGROUND

Uveitis in juvenile idiopathic arthritis (JIAU) is frequently associated with the development of complications and visual loss. Topical corticosteroids are the first line therapy, and disease modifying anti-rheumatic drugs (DMARDs) are commonly used. However, treatment has not been standardized.

METHODS

Interdisciplinary guideline were developed with representatives from the German Ophthalmological Society, Society for Paediatric Rheumatology, Professional Association of Ophthalmologists, German Society for Rheumatology, parents' group, moderated by the Association of the Scientific Medical Societies in Germany. A systematic literature analysis in MEDLINE was performed, evidence and recommendations were graded, an algorithm for anti-inflammatory treatment and final statements were discussed in a consensus meeting (Nominal Group Technique), a preliminary draft was fine-tuned and discussed thereafter by all participants (Delphi procedure).

RESULTS

Consensus was reached on recommendations, including a standardized treatment strategy according to uveitis severity in the individual patient. Thus, methotrexate shall be introduced for uveitis not responding to low-dose (≤ 2 applications/day) topical corticosteroids, and a TNFalpha antibody (preferably adalimumab) used, if uveitis inactivity is not achieved. In very severe active uveitis with uveitis-related deterioration of vision, systemic corticosteroids should be considered for bridging until DMARDs take effect. If TNFalpha antibodies fail to take effect or lose effect, another biological should be selected (tocilizumab, abatacept or rituximab). De-escalation of DMARDs should be preceded by a period of  ≥ 2 years of uveitis inactivity.

CONCLUSIONS

An interdisciplinary, evidence-based treatment guideline for JIAU is presented.

Item Type:

Journal Article (Review Article)

Division/Institute:

04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Ophthalmology

UniBE Contributor:

Tappeiner, Christoph

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0049-0172

Publisher:

Elsevier

Language:

English

Submitter:

Christoph Tappeiner

Date Deposited:

04 Dec 2019 10:13

Last Modified:

04 Dec 2019 10:22

Publisher DOI:

10.1016/j.semarthrit.2018.11.004

PubMed ID:

30595409

Uncontrolled Keywords:

Adolescents Children Consensus Evidence-based medicine Juvenile idiopathic arthritis Rheumatic disease Treatment Uveitis

BORIS DOI:

10.7892/boris.123300

URI:

https://boris.unibe.ch/id/eprint/123300

Actions (login required)

Edit item Edit item
Provide Feedback